Lifecore Biomedical, Inc.
A maker of sterile injectable medicines and medical devices, Lifecore Biomedical is a contract manufacturer producing pharmaceutical-grade sodium hyaluronate—the gel-like substance naturally found in the human eye—used in cataract surgery, orthopedics, and wound care. It traces its roots to 1981 in Chaska, Minnesota, built around the tricky task of making this thick, viscous material, and adopted the name 'Lifecore' in the late 1980s. Its product helps surgeons keep the eye's shape during cataract removal.
Granted 25.9K
Granted 30.0K
Granted 25.9K
Granted 25.9K
Granted 25.9K
Granted 25.9K
Granted 25.9K
Granted 25.9K
Granted 25.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kiper Christopher S +6 co-filersDirector, 10% owner · 1 transaction | +0.6% | 4.51M | 25.9K | — | — |
| Josephs PaulChief Executive Officer, Director · 1 transaction | -6.4% | 592.9K | — | — | — |
| Lake Ryan DavidChief Financial Officer · 1 transaction | -6.4% | 336.7K | — | — | — |
| Salus Thomas D.Chief Legal & Administration · 2 transactions | +2.2% | 246.3K | 30.0K | — | — |
| Obus NelsonDirector · 1 transaction | +18.7% | 164.1K | 25.9K | — | — |
| Houde Lovas KatrinaDirector · 1 transaction | +23.7% | 135.3K | 25.9K | — | — |
| Schechter JoshuaDirector · 1 transaction | +24.2% | 133.1K | 25.9K | — | — |
| Antunes Humberto CalheirosDirector · 1 transaction | +55.1% | 73.0K | 25.9K | — | — |
| Aryeh JasonDirector · 1 transaction | +58.8% | 70.0K | 25.9K | — | — |
| Johnson Paul HaroldDirector · 1 transaction | +58.8% | 70.0K | 25.9K | — | — |
| Korenberg Matthew EDirector · 1 transaction | +58.8% | 70.0K | 25.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.